Merck, known as MSD outside of the United States and Canada, has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware. Part of Merck’s continued commitment to investing in American innovation and infrastructure, Merck Wilmington Biotech will comprise laboratory, manufacturing and warehouse capabilities to enable the launch and commercial production of next-generation biologics and therapies, including potent antibody-drug conjugate...